Introducing new capabilities to GPT-Rosalind

For the micro-dystrophin expression study's identified problems, the source explicitly recommends: (1) for Western blot quantification, "use a recombinant micro-dystrophin standard and an orthogonal method that distinguishes transgene from endogenous dystrophin, such as targeted mass spectrometry or a transgene-specific/epitope-specific assay"; (2) for immunofluorescence, "repeat IF with an antibody against an epitope present in the transgene but absent from revertant dystrophin" and "quantify transgene-positive fibers separately from revertant fibers"; (3) for surrogate endpoint validity, "empirically validate the relationship between micro-dystrophin mass-percent, sarcolemmal localization, downstream functional restoration, and clinical benefit before treating expression as a surrogate endpoint"; and (4) for biopsy design, use matched bilateral sampling strategies that account for spatial variability and disease progression.